– Automatic conversion to be effective March 14, 2022 – NEW YORK, Feb. 23, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that all the Company’s issued and outstanding multiple voting shares (the…

Source

Previous articlePT296 – Dr. David Luke – Vital Psychedelic Conversations
Next articlePsychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?